Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof: Patent #: 8,946,398

Research output: Patent

Standard

Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof : Patent #: 8,946,398 . / Gottwein, Judith Margarete (Inventor); Scheel, Troels Kasper Hoyer (Inventor); Purcell, Robert E (Inventor); Bukh, Jens (Inventor).

Patent No.: WO2011/038737. Feb 03, 2015.

Research output: Patent

Harvard

Gottwein, JM, Scheel, TKH, Purcell, RE & Bukh, J Feb. 03 2015, Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof: Patent #: 8,946,398 , Patent No. WO2011/038737.

APA

Gottwein, J. M., Scheel, T. K. H., Purcell, R. E., & Bukh, J. (2015). Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof: Patent #: 8,946,398 . (Patent No. WO2011/038737).

Vancouver

Gottwein JM, Scheel TKH, Purcell RE, Bukh J, inventors. Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof: Patent #: 8,946,398 . WO2011/038737. 2015 Feb 3.

Author

Gottwein, Judith Margarete (Inventor) ; Scheel, Troels Kasper Hoyer (Inventor) ; Purcell, Robert E (Inventor) ; Bukh, Jens (Inventor). / Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof : Patent #: 8,946,398 . Patent No.: WO2011/038737. Feb 03, 2015.

Bibtex

@misc{ca3c0cf3528546aeaa18a7d6b723d190,
title = "Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof: Patent #: 8,946,398 ",
abstract = "The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.",
author = "Gottwein, {Judith Margarete} and Scheel, {Troels Kasper Hoyer} and Purcell, {Robert E} and Jens Bukh",
year = "2015",
month = feb,
day = "3",
language = "English",
type = "Patent",
note = "WO2011/038737; C07H 21/04 (20060101); C07H 21/02 (20060101)",

}

RIS

TY - PAT

T1 - Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof

T2 - Patent #: 8,946,398

AU - Gottwein, Judith Margarete

AU - Scheel, Troels Kasper Hoyer

AU - Purcell, Robert E

AU - Bukh, Jens

PY - 2015/2/3

Y1 - 2015/2/3

N2 - The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.

AB - The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.

M3 - Patent

M1 - WO2011/038737

Y2 - 2012/07/26

ER -

ID: 140385038